The development of new antileukotriene drugs: specific leukotriene D4 antagonists and 5-lipoxygenase inhibitors.
Rokach
J
J
Merck Frosst Canada, Inc., Pointe Claire-Dorval, Quebec, Canada.
Young
R N
RN
D000818:Animals; D001091:Arachidonate Lipoxygenases / Q000037:antagonists & inhibitors*; D015195:Drug Design; D006168:Guinea Pigs; D006801:Humans; D016859:Lipoxygenase Inhibitors; D015394:Molecular Structure; D011971:Receptors, Immunologic / Q000037:antagonists & inhibitors / Q000378:metabolism; D018077:Receptors, Leukotriene; D013189:SRS-A / Q000037:antagonists & inhibitors*
D016859:Lipoxygenase Inhibitors; D011971:Receptors, Immunologic; D018077:Receptors, Leukotriene; D013189:SRS-A; D001091:Arachidonate Lipoxygenases